- Home
- NML vs MYGN Comparison
NML vs MYGN Comparison
Compare NML & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- MYGN
- Stock Information
- Founded
- NML 2012
- MYGN 1991
- Country
- NML United States
- MYGN United States
- Employees
- NML N/A
- MYGN N/A
- Industry
- NML Finance/Investors Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NML Finance
- MYGN Health Care
- Exchange
- NML Nasdaq
- MYGN Nasdaq
- Market Cap
- NML 487.3M
- MYGN 423.1M
- IPO Year
- NML N/A
- MYGN 1995
- Fundamental
- Price
- NML $8.66
- MYGN $6.10
- Analyst Decision
- NML
- MYGN Hold
- Analyst Count
- NML 0
- MYGN 15
- Target Price
- NML N/A
- MYGN $15.14
- AVG Volume (30 Days)
- NML 219.3K
- MYGN 2.3M
- Earning Date
- NML 01-01-0001
- MYGN 08-05-2025
- Dividend Yield
- NML 9.75%
- MYGN N/A
- EPS Growth
- NML N/A
- MYGN N/A
- EPS
- NML N/A
- MYGN N/A
- Revenue
- NML N/A
- MYGN $832,900,000.00
- Revenue This Year
- NML N/A
- MYGN N/A
- Revenue Next Year
- NML N/A
- MYGN $6.64
- P/E Ratio
- NML N/A
- MYGN N/A
- Revenue Growth
- NML N/A
- MYGN 3.83
- 52 Week Low
- NML $6.09
- MYGN $3.76
- 52 Week High
- NML $7.33
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- NML 46.88
- MYGN 68.58
- Support Level
- NML $8.56
- MYGN $3.76
- Resistance Level
- NML $8.80
- MYGN $4.09
- Average True Range (ATR)
- NML 0.14
- MYGN 0.29
- MACD
- NML 0.01
- MYGN 0.16
- Stochastic Oscillator
- NML 52.94
- MYGN 98.78
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.